Home  |  Contact

Cellosaurus OPM-1 (CVCL_5210)

[Text version]

Cell line name OPM-1
Synonyms OPM1
Accession CVCL_5210
Resource Identification Initiative To cite this cell line use: OPM-1 (RRID:CVCL_5210)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Population: Japanese.
Characteristics: Produces Ig lambda.
Doubling time: 36-42 hours (PubMed=3926660).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Derived from sampling site: Peripheral blood.
Sequence variations Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Heterozygous (CCLE).
Mutation; HGNC; 3690; FGFR3; Simple; p.Lys650Glu (c.1948A>G); ClinVar=VCV000016331; Zygosity=Heterozygous (PubMed=11157491; CCLE).
Mutation; HGNC; 6768; SMAD2; Simple; p.Leu87Arg (c.260T>G); Zygosity=Heterozygous (CCLE).
Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (CCLE).
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.52
Native American0
East Asian, North74.49
East Asian, South22.3
South Asian0
European, North0
European, South2.68
Disease Plasma cell myeloma (NCIt: C3242)
Multiple myeloma (ORDO: Orphanet_29073)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual CVCL_1625 ! OPM-2
Sex of cell Female
Age at sampling 56Y
Category Cancer cell line
STR profile Source(s): Genomics_Center_BCF_Technion

Markers:
AmelogeninX
CSF1PO12,13
D1S165616,17.3
D2S44110
D2S133819,25
D3S135815,18
D5S81813
D7S82012
D8S117910,13
D10S124814
D12S39117,18
D13S31711
D16S5399,13
D18S5113,14,15
D19S43314,14.2
D21S1130,33.2
D22S104511,17
FGA20,21
Penta D9
Penta E12,20,21
TH016,7
TPOX8
vWA14,17

Run an STR similarity search on this cell line
Web pages https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
Publications

PubMed=3926660; DOI=10.1002/ijc.2910360217
Katagiri S., Yonezawa T., Kuyama J., Kanayama Y., Nishida K., Abe T., Tamaki T., Ohnishi M., Tarui S.
Two distinct human myeloma cell lines originating from one patient with myeloma.
Int. J. Cancer 36:241-246(1985)

PubMed=10087940; DOI=10.1016/S0165-4608(98)00157-5
Kuipers J., Vaandrager J.W., Weghuis D.O., Pearson P.L., Scheres J., Lokhorst H.M., Clevers H., Bast B.J.E.G.
Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines.
Cancer Genet. Cytogenet. 109:99-107(1999)

DOI=10.1007/0-306-46877-8_4
Jernberg-Wiklund H., Nilsson K.
Multiple myeloma cell lines.
(In) Human cell culture. Vol. 3. Cancer Cell Lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York (2000)

PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2
Drexler H.G., Matsuo Y.
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.
Leuk. Res. 24:681-703(2000)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=11157491; DOI=10.1182/blood.V97.3.729
Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A., Kuehl W.M., Bergsagel P.L.
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Blood 97:729-736(2001)

PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003
Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J., Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T., Zhu Y.-X., Fogle H., Price-Troska T.L., Ahmann G.J., Mancini C., Brents L.A., Kumar S., Greipp P., Dispenzieri A., Bryant B., Mulligan G., Bruhn L., Barrett M.T., Valdez R., Trent J.M., Stewart A.K., Carpten J., Bergsagel P.L.
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Cancer Cell 12:131-144(2007)

PubMed=18647998; DOI=10.1093/jncimonographs/lgn011
Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.
Characterization of MYC translocations in multiple myeloma cell lines.
J. Natl. Cancer Inst. Monogr. 39:25-31(2008)

CLPUB00604
Chow S.
Targeted capture and sequencing of immunoglobulin rearrangements in multiple myeloma to enable detection of minimal residual disease.
Thesis MSc (2017), University of Toronto, Canada

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

Cross-references
Cell line databases/resources CCLE; OPM1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
Cell_Model_Passport; SIDM00456
DepMap; ACH-000057
Lonza; 28
Biological sample resources BioSample; SAMN10989618
Other Wikidata; Q54936481
Polymorphism and mutation databases Cosmic; 720768
Cosmic; 2081431
Cosmic; 2367299
Entry history
Entry creation04-Apr-2012
Last entry update20-May-2021
Version number19